<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="312">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130985</url>
  </required_header>
  <id_info>
    <org_study_id>NL50754.018.14</org_study_id>
    <nct_id>NCT03130985</nct_id>
  </id_info>
  <brief_title>Tissue, Blood and Biomarkers to Predict Future Atrial Fibrillation</brief_title>
  <acronym>PREDICT-AF</acronym>
  <official_title>PREventive Left Atrial appenDage Resection for predICtion of fuTure Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing coronary artery bypass grafting (CABG), aortic (valve) or mitral valve&#xD;
      surgery are at risk of developing postoperative and new-onset atrial fibrillation (AF), but&#xD;
      adequate risk prediction is currently impossible. This study aims to discover tissue and&#xD;
      circulating microRNAs and protein biomarkers that may help to unravel the pathophysiological&#xD;
      processes underlying AF and are potential tools for risk stratification and prognosis or may&#xD;
      become future targets of therapy.&#xD;
&#xD;
      This study will be a single-center cohort study of 150 patients undergoing cardiac surgery,&#xD;
      which will constitute the beginning of the follow-up period. Left atrial appendages, whole&#xD;
      blood and epicardial mappings will be collected. Patients will be followed for 2 years with&#xD;
      regular holter investigations to detect postoperative and new-onset AF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study procedures:&#xD;
&#xD;
      The left atrial appendage (LAA) will be removed for research and intended prophylactic&#xD;
      purposes, using a surgical stapler or surgical knife prior to the standard procedure.&#xD;
      Epicardial mappings may be performed during cardiac surgery with a 48-multi-electrode.&#xD;
      Patients will be followed with regular 24-hour Holter investigations.&#xD;
&#xD;
      This study will be an exploratory study with a required inclusion of 150 patients, based on&#xD;
      the estimated event rate. Patients will be recruited by the investigators during&#xD;
      pre-operative assessment.&#xD;
&#xD;
      Clinical data will be gathered at baseline and stored in a customized microsoft access entry&#xD;
      database. Statistical analysis will be performed in collaboration with the Bioinformatics&#xD;
      Laboratory from the Academic Medical Center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2015</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 6, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>incident Atrial Fibrillation</measure>
    <time_frame>within 2 years after surgery</time_frame>
    <description>A de novo 30 second continuous rhythm registration of AF, or an ECG recording of an AF episode within 2 years after surgery (with a blanking period for the postoperative period &lt;30 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Atrial Fibrillation</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <description>A 30 second continuous rhythm registration of AF, or an ECG recording of an AF episode in the first 30 days following cardiac surgery or registered at the first 24h Holter monitoring if scheduled within 6 weeks following cardiac surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life defined by 36-Item Short Form Health Survey questionnaire</measure>
    <time_frame>at 6 months and 1 year follow-up</time_frame>
    <description>The quality of life is measured by 36-Item Short Form Health Survey questionnaires.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cardiac surgery patients</arm_group_label>
    <description>The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Left atrial appendages will be deep frozen and fixed Plasma samples and whole blood will be&#xD;
      collected&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients are eligible that are referred to the investigators' tertiary&#xD;
        cardiothoracic center for mitral valve surgery, (aortic) valve surgery or coronary artery&#xD;
        bypass surgery and meet in- and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective sternotomy for either coronary artery bypass surgery or aortic (valve)&#xD;
             surgery or mitral valve surgery&#xD;
&#xD;
          -  CHA2DS2 VASC score ≥ 2&#xD;
&#xD;
          -  Sinus rhythm&#xD;
&#xD;
          -  Age between 18 and 80 years&#xD;
&#xD;
          -  Legally competent and willing and able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to comply with study procedures&#xD;
&#xD;
          -  Documented or reported history of atrial fibrillation, atrial flutter (duration &gt; 5&#xD;
             minutes) or ventricular tachycardia&#xD;
&#xD;
          -  Emergency or redo of CABG&#xD;
&#xD;
          -  Emergency valvular surgery or pericarditis or endocarditis&#xD;
&#xD;
          -  NYHA class IV heart failure symptoms or left ventricular ejection fraction &lt; 35%&#xD;
&#xD;
          -  Pregnancy or of childbearing potential without adequate contraception&#xD;
&#xD;
          -  History of previous radiation therapy of the thorax&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Active inflammtion or auto-immune disease&#xD;
&#xD;
          -  Surgery for congenital anomalies&#xD;
&#xD;
          -  Circumstances that prevent follow-up (no permanent home or address, transient, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joris de Groot, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>North-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.R. de Groot</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>microRNA</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

